Drug Profile

Abciximab biosimilar - Reliance Life Sciences

Alternative Names: AbcixiRel; R-TPR-019

Latest Information Update: 12 Oct 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Reliance Life Sciences
Class Antiplatelets; Fab fragments; Ischaemic heart disorder therapies; Monoclonal antibodies
Mechanism of Action GPIIb-IIIa antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Ischaemic heart disorders; Unstable angina pectoris

Most Recent Events

05 Oct 2020 Abciximab biosimilar licensed to Medicure in USA, Canada and the European Union
30 Sep 2013 Launched for Ischaemic heart disorders (prevention) in India (IV)
30 Sep 2013 Launched for Unstable angina pectoris in India (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com